Co-Authors
This is a "connection" page, showing publications co-authored by DIANE C BODURKA and SHANNON NEVILLE WESTIN.
Connection Strength
1.866
-
Survivors of gynecologic malignancies: impact of treatment on health and well-being. J Cancer Surviv. 2016 Apr; 10(2):261-70.
Score: 0.525
-
Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer. 2011 Jun 15; 117(12):2659-67.
Score: 0.382
-
Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer. Int J Gynecol Cancer. 2021 02; 31(2):232-237.
Score: 0.189
-
Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
Score: 0.186
-
Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol. 2018 01; 131(1):109-116.
Score: 0.155
-
Overall survival after pelvic exenteration for gynecologic malignancy. Gynecol Oncol. 2014 Sep; 134(3):546-51.
Score: 0.122
-
Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol. 2008 Dec 20; 26(36):5965-71.
Score: 0.082
-
Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecol Oncol. 2021 04; 161(1):104-112.
Score: 0.048
-
An Integrated Approach to Selecting a Prepared Medical Decision-Maker. J Pain Symptom Manage. 2021 06; 61(6):1305-1310.
Score: 0.048
-
Systematic Approach to Selecting and Preparing a Medical Power of Attorney in the Gynecologic Oncology Center. J Oncol Pract. 2019 12; 15(12):e1092-e1097.
Score: 0.044
-
Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecol Oncol. 2018 06; 149(3):484-490.
Score: 0.039
-
Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol. 2011 May 01; 121(2):358-63.
Score: 0.024
-
Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer. 2009 Apr 15; 115(8):1598-604.
Score: 0.021